JP7873230B2 - SARS-CoV-2を標的にする抗原結合分子 - Google Patents
SARS-CoV-2を標的にする抗原結合分子Info
- Publication number
- JP7873230B2 JP7873230B2 JP2023513355A JP2023513355A JP7873230B2 JP 7873230 B2 JP7873230 B2 JP 7873230B2 JP 2023513355 A JP2023513355 A JP 2023513355A JP 2023513355 A JP2023513355 A JP 2023513355A JP 7873230 B2 JP7873230 B2 JP 7873230B2
- Authority
- JP
- Japan
- Prior art keywords
- cov
- sars
- antibody
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/102—Coronaviridae (F)
- C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070707P | 2020-08-26 | 2020-08-26 | |
| US63/070,707 | 2020-08-26 | ||
| PCT/US2021/047757 WO2022047033A1 (en) | 2020-08-26 | 2021-08-26 | Antigen binding molecules targeting sars-cov-2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023540037A JP2023540037A (ja) | 2023-09-21 |
| JP2023540037A5 JP2023540037A5 (cg-RX-API-DMAC7.html) | 2024-08-26 |
| JP7873230B2 true JP7873230B2 (ja) | 2026-06-11 |
Family
ID=77897739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513355A Active JP7873230B2 (ja) | 2020-08-26 | 2021-08-26 | SARS-CoV-2を標的にする抗原結合分子 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11987616B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4204446A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7873230B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230058434A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116528897A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021332340A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3188716A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300720A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022047033A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| CA3183373A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| KR20230058434A (ko) | 2020-08-26 | 2023-05-03 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | SARS-CoV-2를 표적으로 하는 항원 결합 분자 |
| AR123469A1 (es) * | 2020-09-10 | 2022-12-07 | Bighat Biosciences Inc | DOMINIOS DE UNIÓN A LA GLICOPROTEÍNA ESPICULAR DEL SARS-CoV(-2) Y POLIPÉPTIDOS QUE LOS COMPRENDEN Y USO DE ESTOS |
| IL316848A (en) | 2022-05-06 | 2025-01-01 | Generate Biomedicines Inc | Antigen-binding molecules targeting SARS-CoV-2 |
| JP2025537301A (ja) | 2022-11-13 | 2025-11-14 | ジェネレイト バイオメディシンズ, インコーポレイテッド | Sars-cov-2を標的とする抗原結合分子 |
| CN117442594A (zh) * | 2023-04-20 | 2024-01-26 | 厦门大学 | 化合物在诊断与治疗新型冠状病毒感染中的应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004260884B2 (en) | 2003-07-22 | 2009-11-19 | Crucell Holland B.V. | Binding molecules against SARS-coronavirus and uses thereof |
| US7622112B2 (en) | 2003-12-05 | 2009-11-24 | Jody Berry | Anti-SARS monoclonal antibodies |
| SG159542A1 (en) | 2004-11-11 | 2010-03-30 | Crucell Holland Bv | Compositions against sars-coronavirus and uses thereof |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| KR101616758B1 (ko) | 2007-12-26 | 2016-04-29 | 젠코어 인코포레이티드 | FcRn에 대한 변경된 결합성을 갖는 Fc 변이체 |
| MY177098A (en) | 2013-08-09 | 2020-09-05 | Astellas Pharma Inc | Novel anti-human tslp receptor antibody |
| MX2017004103A (es) | 2014-10-01 | 2017-07-07 | Medimmune Ltd | Proteinas de union especificas para el receptor 1 de lipoproteinas de baja densidad oxidadas de tipo lectina (lox1) y sus usos. |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| US20220089752A1 (en) | 2019-01-14 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for modulating cellular internalization |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
| US20250263466A1 (en) | 2020-02-03 | 2025-08-21 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
| WO2021156490A2 (en) * | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
| HUE062777T2 (hu) | 2020-02-26 | 2023-12-28 | Vir Biotechnology Inc | SARS-CoV-2 elleni antitestek |
| EP4121454A1 (en) | 2020-03-19 | 2023-01-25 | Imperial College Innovations Limited | Coronavirus antibody |
| US11028167B1 (en) | 2020-03-23 | 2021-06-08 | Centivax, Inc. | Anti-SARS-Cov-2 antibodies derived from 3bgf |
| CR20220552A (es) | 2020-04-02 | 2023-01-17 | Regeneron Pharma | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno |
| WO2021203053A1 (en) | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
| US20230348571A1 (en) | 2020-04-06 | 2023-11-02 | Vanderbilt University | Cross-reactive coronavirus antibodies and uses thereof |
| US11192940B2 (en) | 2020-04-10 | 2021-12-07 | Adagio Therapeutics, Inc. | Compounds specific to coronavirus S protein and uses thereof |
| BR112022020706A2 (pt) | 2020-04-14 | 2022-11-29 | Vir Biotechnology Inc | Anticorpos contra sars-cov-2 e métodos de uso dos mesmos |
| CN115461364B (zh) | 2020-04-28 | 2025-12-16 | 北京大学 | 一种抗新型冠状病毒的单克隆抗体及其应用 |
| PH12022500020A1 (en) | 2020-05-08 | 2024-05-06 | Vir Biotechnology Inc | Antibodies against sars-cov-2 |
| WO2021247925A1 (en) | 2020-06-03 | 2021-12-09 | Vir Biotechnology, Inc. | Structure-guided immunotherapy against sars-cov-2 |
| CA3183373A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| WO2022015573A2 (en) | 2020-07-13 | 2022-01-20 | President And Fellows Of Harvard College | Sars-cov-2 antigen-binding proteins and uses thereof |
| US20230058162A1 (en) | 2020-07-27 | 2023-02-23 | Igm Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
| WO2022046888A1 (en) | 2020-08-25 | 2022-03-03 | Target Discovery Merger Sub II, LLC | Sars-cov-2 associated antibody compositions and methods of use |
| KR20230058434A (ko) | 2020-08-26 | 2023-05-03 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | SARS-CoV-2를 표적으로 하는 항원 결합 분자 |
| KR20230127305A (ko) | 2020-12-29 | 2023-08-31 | 발-첨, 리미티드 파트너십 | Covid-19에 대한 중화 단일클론 항체 |
| US20240101646A1 (en) | 2021-01-22 | 2024-03-28 | Vanderbilt University | Sars-cov-2 coronavirus antibodies and uses thereof |
| WO2022204202A1 (en) | 2021-03-23 | 2022-09-29 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| KR20240035758A (ko) | 2021-05-24 | 2024-03-18 | 비르 바이오테크놀로지, 인코포레이티드 | 조작된 폴리펩타이드 |
| WO2022271863A1 (en) | 2021-06-23 | 2022-12-29 | Chan Zuckerberg Biohub, Inc. | Coronavirus neutralizing compositions and associated methods |
| WO2023028603A2 (en) | 2021-08-27 | 2023-03-02 | Humabs Biomed Sa | Engineered compositions |
| EP4147716A1 (en) | 2021-09-10 | 2023-03-15 | Samatva Research Corporation | Anti-virus moiety immobilised in a matrix |
| IL316848A (en) | 2022-05-06 | 2025-01-01 | Generate Biomedicines Inc | Antigen-binding molecules targeting SARS-CoV-2 |
-
2021
- 2021-08-26 KR KR1020237009720A patent/KR20230058434A/ko active Pending
- 2021-08-26 IL IL300720A patent/IL300720A/en unknown
- 2021-08-26 CA CA3188716A patent/CA3188716A1/en active Pending
- 2021-08-26 EP EP21773945.7A patent/EP4204446A1/en active Pending
- 2021-08-26 JP JP2023513355A patent/JP7873230B2/ja active Active
- 2021-08-26 CN CN202180052278.1A patent/CN116528897A/zh active Pending
- 2021-08-26 WO PCT/US2021/047757 patent/WO2022047033A1/en not_active Ceased
- 2021-08-26 AU AU2021332340A patent/AU2021332340A1/en active Pending
-
2023
- 2023-02-15 US US18/169,464 patent/US11987616B2/en active Active
Non-Patent Citations (2)
| Title |
|---|
| Accession No. MT350284.1,GenBank [online],[検索日 2025.07.29],2020年05月,<URL:https://www.ncbi.nlm.nih.gov/nuccore/MT350284.1/> |
| Daniel WRAPP et al.,Cell,2020年05月,Vol. 181, No. 5,p.1005-1015 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4204446A1 (en) | 2023-07-05 |
| CA3188716A1 (en) | 2022-03-03 |
| IL300720A (en) | 2023-04-01 |
| KR20230058434A (ko) | 2023-05-03 |
| CN116528897A (zh) | 2023-08-01 |
| US11987616B2 (en) | 2024-05-21 |
| US20230287089A1 (en) | 2023-09-14 |
| JP2023540037A (ja) | 2023-09-21 |
| AU2021332340A1 (en) | 2023-10-05 |
| AU2021332340A9 (en) | 2024-05-09 |
| WO2022047033A1 (en) | 2022-03-03 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240816 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240816 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250731 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251031 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260408 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260508 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260601 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7873230 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |